What question did this study set out to answer?

The study aims to assess how the COVID-19 pandemic affected the management of prostate cancer patients at a tertiary medical center by comparing pre-pandemic and pandemic treatment approaches.

January 18, 2026Prostate CancerOpen Access

Change in Clinical Management of Localized Prostate Cancer Patients at a Tertiary Medical Center as a Result of SARS‐CoV‐2 (COVID‐19)

View Full Paper

Ask AI

Bookmark

Authors

AYAlexander YaneyThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute JSJonathan E. SchoenhalsThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute YGY. GokunThe Ohio State University Wexner Medical Center

Discussion

Member takes

Implication

Reveals changes in prostate cancer management during COVID-19, suggesting adaptations in clinical approaches.

Key Points

The study aims to assess how the COVID-19 pandemic affected the management of prostate cancer patients at a tertiary medical center by comparing pre-pandemic and pandemic treatment approaches.
Retrospective review of prostate cancer patients treated in 2019-2020.
Comparison of treatment timelines before and during COVID-19 using descriptive statistics.
Statistical analyses included chi-squared tests and binary logistic regressions to evaluate treatment differences.
Patients experienced longer time-to-treatment during COVID (median 126.5 days) compared to pre-COVID (median 111 days), p = 0.007.
Time from androgen deprivation therapy initiation to treatment start increased significantly during COVID for definitive RT (median 78 days vs. 147 days) and salvage RT (median 67 days vs. 84 days).
A higher percentage of patients received androgen deprivation therapy prior to surgery in the COVID cohort (9.8% vs. 0.5%, p < 0.001).
Higher-risk prostate cancer patients had increased odds of receiving treatment during the pandemic (adjusted odds ratio 1.62, 95% CI: 1.02–2.55).

Cite This Study

Yaney et al. (2026) studied this question.

synapsesocial.com/papers/696c7791eb60fb80d1395d49 https://doi.org/10.1155/proc/9996270

View Full Paper

Ask AI

Bookmark

Change in Clinical Management of Localized Prostate Cancer Patients at a Tertiary Medical Center as a Result of SARS‐CoV‐2 (COVID‐19)

Discussion

Member takes

Implication

Key Points

Cite This Study

Change in Clinical Management of Localized Prostate Cancer Patients at a Tertiary Medical Center as a Result of SARS‐CoV‐2 (COVID‐19)

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider